InChi: InChI=1S/C59H71ClFN11O7S/c1-37(61)56(76)71-27-26-70(32-42(71)19-22-62)54-45-20-25-69(48-14-7-11-40-10-6-13-46(60)51(40)48)34-47(45)65-58(67-54)79-35-43-12-8-23-68(43)24-9-28-78-29-21-50(74)66-53(59(3
3 min) increases particulate cGMP- and cilostamide-inhibited
Treatment with the glycogen synthase kinase-3beta inhibitor
Smiles: CN(C)C/C=C/C(=O)NC1C=CC(=CC=1)C(=O)NC1=CC(=CC=C1)NC1=NC(=C(Cl)C=N1)C1=CNC2=CC=CC=C21
Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats
Elacridar tilonium Bromide InChi: InChI=1S/C59H71ClFN11O7S/c1-37(61)56(76)71-27-26-70(32-42(71)19-22-62)54-45-20-25-69(48-14-7-11-40-10-6-13-46(60)51(40)48)34-47(45)65-58(67-54)79-35-43-12-8-23-68(43)24-9-28-78-29-21-50(74)66-53(59(3Elacridar, also known as GF120918A, is a P glycoprotein (P gp) inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. In vitro, GF120918A demonstrated high plasma protein binding across species, although a definitive protein binding evaluation was precluded by poor recovery, particularly in buffer and in mouse, rat, and dog
